SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long term, according to a study from the UK and Ireland.
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...
US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...
Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...
As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...
Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment.
No dedicated clinical trials have compared denosumab and bisphosphonates for fracture prevention in patients on dialysis.
Dr. Reddy’s is focusing on a pipeline of complex drugs, including GLP-1s (such as Semaglutide) as well as biosimilars and consumer care to offset the loss of exclusivity for its blockbuster drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback